_id
6910577dccc777a4e85d568d
Ticker
CVKD
Name
Cadrenal Therapeutics, Inc. Common Stock
Exchange
NASDAQ
Address
822 A1A North, Ponte Vedra, FL, United States, 32082
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.cadrenal.com
Description
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Last Close
6.62
Volume
19592
Current Price
7.32
Change
0.16
Last Updated
2026-01-02T12:14:57.560Z
Image
data:image/webp;base64,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
Ipo Date
2023-01-20T00:00:00.000Z
Market Cap
15852502
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.979
Sentiment Sources
1
Rating
4.5
Target Price
35.6667
Strong Buy
1
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
401
Gross Profit
-401
Operating Expenses
2733402
Operating Income
-2733803
Interest Expense
-
Pretax Income
-2685705
Net Income
-2685705
Eps
-1.3139244816497582
Dividends Per Share
-
Shares Outstanding
2338127
Income Tax Expense
-
EBITDA
-2685304
Operating Margin
-
Total Other Income Expense Net
48098
Cash
3860082
Short Term Investments
-
Receivables
12791
Inventories
-
Total Current Assets
4079726
Property Plant Equipment
5729
Total Assets
4087622
Payables
614127
Short Term Debt
-
Long Term Debt
-
Total Liabilities
1352675
Equity
2734947
Bs_currency_symbol
USD
Depreciation
401
Change In Working Capital
-145230
Cash From Operations
-2357150
Capital Expenditures
1850
Cash From Investing
-1853
Cash From Financing
648355
Net Change In Cash
-1710648
Cf_currency_symbol
USD
PE
-
PB
5.470790315132249
ROE
-98.19952635279586
ROA
-65.70336004650137
FCF
-2359000
Fcf Percent
-
Piotroski FScore
1
Health Score
38
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
401
Quarters > 0 > income Statement > gross Profit
-401
Quarters > 0 > income Statement > operating Expenses
2733402
Quarters > 0 > income Statement > operating Income
-2733803
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-2685705
Quarters > 0 > income Statement > net Income
-2685705
Quarters > 0 > income Statement > eps
-1.3139244816497582
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
2044033
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-2685304
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
48098
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
3860082
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
12791
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
4079726
Quarters > 0 > balance Sheet > property Plant Equipment
5729
Quarters > 0 > balance Sheet > total Assets
4087622
Quarters > 0 > balance Sheet > payables
614127
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
1352675
Quarters > 0 > balance Sheet > equity
2734947
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-2685705
Quarters > 0 > cash Flow > depreciation
401
Quarters > 0 > cash Flow > change In Working Capital
-145230
Quarters > 0 > cash Flow > cash From Operations
-2357150
Quarters > 0 > cash Flow > capital Expenditures
1850
Quarters > 0 > cash Flow > cash From Investing
-1853
Quarters > 0 > cash Flow > cash From Financing
648355
Quarters > 0 > cash Flow > net Change In Cash
-1710648
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-1.3139244816497582
Quarters > 0 > ratios > PB
5.470790315132249
Quarters > 0 > ratios > ROE
-98.19952635279586
Quarters > 0 > ratios > ROA
-65.70336004650137
Quarters > 0 > ratios > FCF
-2359000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
401
Quarters > 1 > income Statement > gross Profit
-401
Quarters > 1 > income Statement > operating Expenses
3734291
Quarters > 1 > income Statement > operating Income
-3734291
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-3667287
Quarters > 1 > income Statement > net Income
-3667287
Quarters > 1 > income Statement > eps
-1.8694986139163008
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
1961642
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-3733890
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
67004
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
5570730
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
19039
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
5971987
Quarters > 1 > balance Sheet > property Plant Equipment
4277
Quarters > 1 > balance Sheet > total Assets
5978431
Quarters > 1 > balance Sheet > payables
895609
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
1679518
Quarters > 1 > balance Sheet > equity
4298913
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-3667287
Quarters > 1 > cash Flow > depreciation
401
Quarters > 1 > cash Flow > change In Working Capital
48440
Quarters > 1 > cash Flow > cash From Operations
-3025802
Quarters > 1 > cash Flow > capital Expenditures
3255
Quarters > 1 > cash Flow > cash From Investing
3251
Quarters > 1 > cash Flow > cash From Financing
1260460
Quarters > 1 > cash Flow > net Change In Cash
-1765342
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-1.8694986139163008
Quarters > 1 > ratios > PB
3.340197729053833
Quarters > 1 > ratios > ROE
-85.30730908022562
Quarters > 1 > ratios > ROA
-61.341964137413306
Quarters > 1 > ratios > FCF
-3029057
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
38
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
5517
Quarters > 2 > income Statement > gross Profit
-5517
Quarters > 2 > income Statement > operating Expenses
3922459
Quarters > 2 > income Statement > operating Income
-3927976
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-3845380
Quarters > 2 > income Statement > net Income
-3845380
Quarters > 2 > income Statement > eps
-2.0852656512327066
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
1844072
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-3839863
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
82596
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
7336072
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
24664
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
7944792
Quarters > 2 > balance Sheet > property Plant Equipment
4678
Quarters > 2 > balance Sheet > total Assets
7953262
Quarters > 2 > balance Sheet > payables
1278402
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
1840166
Quarters > 2 > balance Sheet > equity
6113096
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-3845380
Quarters > 2 > cash Flow > depreciation
5517
Quarters > 2 > cash Flow > change In Working Capital
-1357657
Quarters > 2 > cash Flow > cash From Operations
-4648755
Quarters > 2 > cash Flow > capital Expenditures
3255
Quarters > 2 > cash Flow > cash From Investing
-3251
Quarters > 2 > cash Flow > cash From Financing
1970136
Quarters > 2 > cash Flow > net Change In Cash
-2681870
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-2.0852656512327066
Quarters > 2 > ratios > PB
2.208145764437529
Quarters > 2 > ratios > ROE
-62.9039687909367
Quarters > 2 > ratios > ROA
-48.34972115843789
Quarters > 2 > ratios > FCF
-4652010
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
42
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
2134
Quarters > 3 > income Statement > cost Of Revenue
1067
Quarters > 3 > income Statement > gross Profit
1067
Quarters > 3 > income Statement > operating Expenses
4278428
Quarters > 3 > income Statement > operating Income
-4278428
Quarters > 3 > income Statement > interest Expense
0
Quarters > 3 > income Statement > pretax Income
-4187269
Quarters > 3 > income Statement > net Income
-4187269
Quarters > 3 > income Statement > eps
-2.7457411615043883
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
1525005
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-4186862
Quarters > 3 > income Statement > operating Margin
-200488.65979381444
Quarters > 3 > income Statement > total Other Income Expense Net
91159
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
10017942
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
38153
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
10112797
Quarters > 3 > balance Sheet > property Plant Equipment
6944
Quarters > 3 > balance Sheet > total Assets
10123533
Quarters > 3 > balance Sheet > payables
1502468
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
2683958
Quarters > 3 > balance Sheet > equity
7439575
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-4187269
Quarters > 3 > cash Flow > depreciation
407
Quarters > 3 > cash Flow > change In Working Capital
1632983
Quarters > 3 > cash Flow > cash From Operations
-1790706
Quarters > 3 > cash Flow > capital Expenditures
6537
Quarters > 3 > cash Flow > cash From Investing
-6537
Quarters > 3 > cash Flow > cash From Financing
7451285
Quarters > 3 > cash Flow > net Change In Cash
5654042
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-2.7457411615043883
Quarters > 3 > ratios > PB
1.500493858856185
Quarters > 3 > ratios > ROE
-56.28371244325112
Quarters > 3 > ratios > ROA
-41.36173606585764
Quarters > 3 > ratios > FCF
-1797243
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-842.1944704779756
Quarters > 3 > health Score
35
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
1880
Annuals > 0 > income Statement > gross Profit
-1880
Annuals > 0 > income Statement > operating Expenses
10960619
Annuals > 0 > income Statement > operating Income
-10960619
Annuals > 0 > income Statement > interest Expense
0
Annuals > 0 > income Statement > pretax Income
-10651368
Annuals > 0 > income Statement > net Income
-10651368
Annuals > 0 > income Statement > eps
-8.73385101061867
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
1219550
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-10649488
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
309251
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
10017942
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
38153
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
10112797
Annuals > 0 > balance Sheet > property Plant Equipment
6944
Annuals > 0 > balance Sheet > total Assets
10123533
Annuals > 0 > balance Sheet > payables
1502468
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
2683958
Annuals > 0 > balance Sheet > equity
7439575
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-10651368
Annuals > 0 > cash Flow > depreciation
1880
Annuals > 0 > cash Flow > change In Working Capital
1873251
Annuals > 0 > cash Flow > cash From Operations
-7357550
Annuals > 0 > cash Flow > capital Expenditures
6537
Annuals > 0 > cash Flow > cash From Investing
-6537
Annuals > 0 > cash Flow > cash From Financing
8979529
Annuals > 0 > cash Flow > net Change In Cash
1615442
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-8.73385101061867
Annuals > 0 > ratios > PB
1.1114276017111193
Annuals > 0 > ratios > ROE
-143.17172687955966
Annuals > 0 > ratios > ROA
-105.2139406272494
Annuals > 0 > ratios > FCF
-7364087
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
35
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
1980
Annuals > 1 > income Statement > gross Profit
-1980
Annuals > 1 > income Statement > operating Expenses
7632843
Annuals > 1 > income Statement > operating Income
-7632843
Annuals > 1 > income Statement > interest Expense
17101
Annuals > 1 > income Statement > pretax Income
-8357086
Annuals > 1 > income Statement > net Income
-8357086
Annuals > 1 > income Statement > eps
-9.625949828549972
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
868183
Annuals > 1 > income Statement > income Tax Expense
-165915
Annuals > 1 > income Statement > EBITDA
-8338005
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-724243
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
8402500
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
8492173
Annuals > 1 > balance Sheet > property Plant Equipment
23285
Annuals > 1 > balance Sheet > total Assets
8519250
Annuals > 1 > balance Sheet > payables
167319
Annuals > 1 > balance Sheet > short Term Debt
21350
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
826875
Annuals > 1 > balance Sheet > equity
7692375
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-8357086
Annuals > 1 > cash Flow > depreciation
1980
Annuals > 1 > cash Flow > change In Working Capital
144309
Annuals > 1 > cash Flow > cash From Operations
-3530323
Annuals > 1 > cash Flow > capital Expenditures
3254
Annuals > 1 > cash Flow > cash From Investing
-3254
Annuals > 1 > cash Flow > cash From Financing
11903491
Annuals > 1 > cash Flow > net Change In Cash
8369914
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-9.625949828549972
Annuals > 1 > ratios > PB
0.7652098006142447
Annuals > 1 > ratios > ROE
-108.64116738978534
Annuals > 1 > ratios > ROA
-98.09649910496816
Annuals > 1 > ratios > FCF
-3533577
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
-
Annuals > 2 > income Statement > cost Of Revenue
1266
Annuals > 2 > income Statement > gross Profit
-1266
Annuals > 2 > income Statement > operating Expenses
2700362
Annuals > 2 > income Statement > operating Income
-2701630
Annuals > 2 > income Statement > interest Expense
107105
Annuals > 2 > income Statement > pretax Income
-6714329
Annuals > 2 > income Statement > net Income
-6714329
Annuals > 2 > income Statement > eps
-8.656524048589677
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
775638
Annuals > 2 > income Statement > income Tax Expense
4
Annuals > 2 > income Statement > EBITDA
-6605958
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-4012699
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
32586
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
727596
Annuals > 2 > balance Sheet > property Plant Equipment
44591
Annuals > 2 > balance Sheet > total Assets
778174
Annuals > 2 > balance Sheet > payables
404897
Annuals > 2 > balance Sheet > short Term Debt
66016
Annuals > 2 > balance Sheet > long Term Debt
553340
Annuals > 2 > balance Sheet > total Liabilities
6329324
Annuals > 2 > balance Sheet > equity
-5551150
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-6714329
Annuals > 2 > cash Flow > depreciation
1266
Annuals > 2 > cash Flow > change In Working Capital
607735
Annuals > 2 > cash Flow > cash From Operations
-1204770
Annuals > 2 > cash Flow > capital Expenditures
2486
Annuals > 2 > cash Flow > cash From Investing
-2279
Annuals > 2 > cash Flow > cash From Financing
1239635
Annuals > 2 > cash Flow > net Change In Cash
32585
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-8.656524048589677
Annuals > 2 > ratios > PB
-0.9473398557055747
Annuals > 2 > ratios > ROE
120.95383839384633
Annuals > 2 > ratios > ROA
-862.8313205015845
Annuals > 2 > ratios > FCF
-1207256
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
38
Valuation > metrics > PE
-1.3139244816497582
Valuation > metrics > PB
5.470790315132249
Valuation > final Score
25.29209684867751
Valuation > verdict
82.4% Overvalued
Profitability > metrics > ROE
-98.19952635279586
Profitability > metrics > ROA
-65.83052391263531
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.49458910903940734
Risk > metrics > Interest Coverage
-6817.463840399003
Risk > final Score
-27210
Risk > verdict
High
Liquidity > metrics > Current Ratio
6.643130818218381
Liquidity > metrics > Quick Ratio
6.643130818218381
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
46.59802270946167
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-164
Prev Risks > 1
-2788
Prev Risks > 2
-41988
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:40:47.116Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-06
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-1.31
Earnings History > 0 > eps Estimate
-1.39
Earnings History > 0 > eps Difference
0.08
Earnings History > 0 > surprise Percent
5.7554
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-11
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-1.87
Earnings History > 1 > eps Estimate
-1.26
Earnings History > 1 > eps Difference
-0.61
Earnings History > 1 > surprise Percent
-48.4127
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-08
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-2.09
Earnings History > 2 > eps Estimate
-2.15
Earnings History > 2 > eps Difference
0.06
Earnings History > 2 > surprise Percent
2.7907
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-13
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-2.55
Earnings History > 3 > eps Estimate
-0.15
Earnings History > 3 > eps Difference
-2.4
Earnings History > 3 > surprise Percent
-1600
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-07
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-2.18
Earnings History > 4 > eps Estimate
-0.12
Earnings History > 4 > eps Difference
-2.06
Earnings History > 4 > surprise Percent
-1716.6667
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-07
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-2.25
Earnings History > 5 > eps Estimate
-0.12
Earnings History > 5 > eps Difference
-2.13
Earnings History > 5 > surprise Percent
-1775
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-09
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.1
Earnings History > 6 > eps Estimate
-0.07
Earnings History > 6 > eps Difference
-0.03
Earnings History > 6 > surprise Percent
-42.8571
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2024-03-11
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.05
Earnings History > 7 > eps Estimate
-0.08
Earnings History > 7 > eps Difference
0.03
Earnings History > 7 > surprise Percent
37.5
Earnings History > 8 > period
2023-09-30
Earnings History > 8 > report Date
2023-11-11
Earnings History > 8 > date
2023-09-30
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.0796
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2023-06-30
Earnings History > 9 > report Date
2023-08-30
Earnings History > 9 > date
2023-06-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-1.35
Earnings History > 9 > eps Estimate
-
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-03-31
Earnings History > 10 > report Date
2023-03-31
Earnings History > 10 > date
2023-03-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-6.6199
Earnings History > 10 > eps Estimate
-
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2022-12-31
Earnings History > 11 > report Date
2023-03-30
Earnings History > 11 > date
2022-12-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-0.85
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
-0.85
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2022-06-30
Earnings History > 12 > report Date
2022-09-22
Earnings History > 12 > date
2022-06-30
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-0.06
Earnings History > 12 > eps Estimate
0
Earnings History > 12 > eps Difference
-0.06
Earnings History > 12 > surprise Percent
-
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AWhy Is Cadrenal Therapeutics Stock Drawing Retail Attention Today? Stocktwits
Read more →How CVKD stock reacts to inflationary pressures - Weekly Gains Report & Risk Managed Investment Signals bollywoodhelpline.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$35.6667
Analyst Picks
Strong Buy
1
Buy
1
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Cadrenal Therapeutics, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-1.31
EPS Estimate
-1.39
EPS Difference
0.08
Surprise Percent
5.7554%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.